Quantcast

Latest Cetuximab Stories

2014-02-14 08:26:33

Clinical and Regulatory Plans for Two Lead Products Announced SAN DIEGO, Feb. 14, 2014 /PRNewswire/ -- MultiVir, a leader in gene therapies for cancer treatment, presented to the investment community at the Leerink Global Healthcare Conference. Highlights of the presentation included an overview of the development plans for the company's two lead products which are supported by strong pre-clinical and clinical data. MultiVir's adenoviral p53 (Ad-p53) and adenoviral interleukin 24...

2014-01-30 12:28:48

International studies demonstrate importance of comprehensive tumor profiling for poor-prognosis cancer patients IRVING, Texas, Jan. 30, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present two tumor profiling studies at the 2014 Genitourinary Cancers Symposium held this week in San Francisco, Calif. Through use of the company's comprehensive tumor profiling service, Caris Molecular Intelligence,...

2014-01-30 12:28:09

AUSTIN, Texas, Jan. 30, 2014 /PRNewswire/ -- XBiotech announced today that its collaboration with the European Medicines Agency (EMA) has resulted in establishment of a regulatory path for Xilonix(TM) registration in the European Union for the treatment of colorectal cancer. XBiotech AG will soon launch its Phase III registration study in Europe to evaluate Xilonix in patients with treatment-resistant colorectal cancer. Cancer treatment centers in at least 6 countries will be involved...

2014-01-18 08:20:15

Research findings enable disease molecular sub-typing to lead to more informed clinical decision-making IRVING, Texas, Jan. 18, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by...

2014-01-08 11:39:15

University of Cincinnati (UC) Cancer Institute researchers have found that using therapies specifically targeting the molecular profile of non-small-cell lung cancer with the mutated cancer-causing protein KRas is the most effective treatment strategy for patients with the condition. These findings are being presented via poster at the American Association for Cancer Research– International Association for the Study of Lung Cancer Joint Conference on the Molecular Origins of Lung Cancer,...

2014-01-06 04:21:59

SAN DIEGO and THE WOODLANDS, Texas, Jan. 6, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, and US Oncology Research, one of the largest community-based research programs in the United States, announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of...

2013-12-30 08:26:41

LONDON, Dec. 30, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Colorectal Cancer -- KOL Insight Module IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies. What will be the impact on market leader Roche/Genetech's Avastin and how do leading clinicians view the changes? The main drivers...

2013-12-25 23:01:37

ResearchMoz.us include new market research report " Global and China Monoclonal Antibody Industry Report, 2013 - 2017 " to its huge collection of research reports. Browse full report - http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html Albany, NY (PRWEB) December 25, 2013 Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the...

2013-12-18 23:24:54

RnRMarketResearch.com adds “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth” latest report to its store. Dallas, TX (PRWEB) December 18, 2013 There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin,...


Word of the Day
out-herod
  • In the phrase to out-herod Herod, to be more violent than Herod (as represented in the old mystery plays); hence, to exceed in any excess of evil.
Herod refers to 'Herod the Great,' a Roman client king and 'a madman who murdered his own family and a great many rabbis.' According to the OED, the term is 'chiefly with allusion to Shakespeare's use' in Hamlet.
Related